Urachal Cancer in Germany and the USA: An RKI/SEER Population-Based Comparison Study

Abstract

Introduction: Urachal cancer (UrC) is a rare but aggressive cancer. Due to its low incidence, structured epidemiological data have only rarely been reported. To date, no valid data on UrC are available for the German population. Methods: Data on incidence and relative 5-year survival of urachal lesions (ICD-10: C67.7) were collected from all populationbased cancer registries in Germany, provided by the Robert Koch-Institut (RKI). Data were anonymized and included age, sex, and general histology (ICD-O-3). For comparison, a similar inquiry of the "Surveillance, Epidemiology, and End Results program" (SEER-18) database for the USA was conducted. Results: From 2011 to 2015, a total of 154 and 152 cases of UrC were reported for Germany (RKI) and the USA (SEER-18 area), respectively. Age-standardized incidence was 0.32/1,000,000 age-standardized cases/year in both cohorts, and elderly persons were more often affected. The major histological type was adenocarcinoma (64.9 and 81.6%). Relative 5-year survival was 54.8% (CI: 45.0-64.6) in Germany (RKI) and 64.4% (54.1-72.1) in the USA (SEER-18 cohort). Discusssion/Conclusion: The collected data demonstrate low incidence rates and similar epidemiological and clinicopathological characteristics of UrC for both registries. This is the first report of structured epidemiological data for UrC for the German population.

Treatment Outcome of Different Chemotherapy in Patients With Relapsed or Metastatic Malignant Urachal Tumor

“…NGS in seven cases revealed a prevalence of TP53 mutation. Some population-based cohort reported the clinical outcome and prognostic factors in MUT (3,7,12). Hager et al reported 154 and 152 cases of MUT in Germany and SEER database from 2011 to 2015, respectively; the relative 5 year-survival rates were 54.8% in Germany and 64.4% in the United States (7).…”

“…Some population-based cohort reported the clinical outcome and prognostic factors in MUT (3,7,12). Hager et al reported 154 and 152 cases of MUT in Germany and SEER database from 2011 to 2015, respectively; the relative 5 year-survival rates were 54.8% in Germany and 64.4% in the United States (7). Another population-based study, which summarized 152 cases of MUT in Netherlands, reported that only 13 out of 45 patients in stage IV received chemotherapy, with poor survival (3).…”

“…Some population-based cohort reported the clinical outcome and prognostic factors in MUT ( 3 , 7 , 12 ). Hager et al.…”

“…Literatures about MUT are mainly based on some of case reports and few retrospective studies (3)(4)(5)(6). MUT mostly affects male patients at 50 to 60 years (3,7). The common clinical manifestation is hematuria (8,9).…”

A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer

“…While macroscopic residues are uncommon, microscopic urachal remnants can be detected in up to 32% of adults [2]. With an incidence of <1 case per 1,000,000 people per year, urachal cancer can rarely arise from these remnants with urachal adenocarcinomas (UrC) accounting for over 90% of cases [3][4][5][6]. Non-cystic type UrC mostly (57%) exhibit a mucinous histology followed by intestinal, not otherwise specified (NOS), mixed, and signet ring cell histology subtypes [4,7].…”